Literature DB >> 20346312

Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock.

René J van der Schaaf1, Bimmer E Claessen, M Marije Vis, Loes P Hoebers, Karel T Koch, Jan Baan, Martijn Meuwissen, Annemarie E Engstrom, Wouter J Kikkert, Jan G P Tijssen, Robbert J de Winter, Jan J Piek, José P S Henriques.   

Abstract

Despite early revascularization, mortality remains high in patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock. It has been shown that the effect of multivessel disease (MVD) on mortality in patients with STEMI treated with primary percutaneous coronary intervention is mainly caused by the presence of chronic total occlusion (CTO) in a noninfarct-related coronary artery. Whether this association also exists in patients with STEMI with cardiogenic shock is unknown. In our institution, 292 consecutive patients with STEMI complicated by cardiogenic shock were admitted from 1997 to 2005 and treated with primary percutaneous coronary intervention. Patients were classified as having single vessel disease, MVD without CTO, and CTO. Cox regression analysis was used for multivariate analysis. The 1-year mortality rate of patients with single-vessel disease, MVD, and CTO was 31%, 47%, and 63%, respectively. After adjustment for possible confounders, MVD alone was not an independent predictor of 1-year mortality (hazard ratio 1.5, 95% confidence interval 0.98 to 2.3, p = 0.07). In contrast, CTO in a noninfarct-related artery was an independent predictor of 1-year mortality (hazard ratio 2.1, 95% confidence interval 1.5 to 3.1, p <0.01). In conclusion, the presence of CTO in a non-infarct-related artery was an independent predictor of 1-year mortality. In contrast, MVD alone lost its predictive significance after multivariate analysis. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20346312     DOI: 10.1016/j.amjcard.2009.11.014

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

Review 1.  Ubiquitin-free routes into the proteasome.

Authors:  M A Hoyt; P Coffino
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

Review 2.  Multivessel versus culprit-only revascularization: one time versus staged procedures for the ACS population.

Authors:  Pablo Codner; Ran Kornowski
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

Review 3.  Phagocytosis of apoptotic cells: a matter of balance.

Authors:  C J G de Almeida; R Linden
Journal:  Cell Mol Life Sci       Date:  2005-07       Impact factor: 9.261

Review 4.  Familial hypobetalipoproteinemia: genetics and metabolism.

Authors:  G Schonfeld; X Lin; P Yue
Journal:  Cell Mol Life Sci       Date:  2005-06       Impact factor: 9.261

5.  Efficacy and timing of intra-aortic counterpulsation in patients with ST-elevation myocardial infarction complicated by cardiogenic shock.

Authors:  K D Sjauw; A E Engström; M M Vis; W Boom; J Baan; R J de Winter; J G P Tijssen; J J Piek; J P S Henriques
Journal:  Neth Heart J       Date:  2012-10       Impact factor: 2.380

6.  [Procedural aspects in primary PCI: arterial access, stent selection, thrombectomy and treatment of non-culprit lesions].

Authors:  N F Boeder; C W Hamm; H M Nef
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

Review 7.  [Immediate multivessel PCI in patients with ACS : Is less more?]

Authors:  U Zeymer; R Zahn
Journal:  Herz       Date:  2016-11       Impact factor: 1.443

Review 8.  Interventional therapies in acute myocardial infarction complicated by cardiogenic shock.

Authors:  S de Waha; S Desch; G Fuernau; J Pöss; J Ledwoch; A Jobs; I Eitel; H Thiele
Journal:  Herz       Date:  2017-02       Impact factor: 1.443

9.  Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.

Authors:  René J van der Schaaf; Bimmer E Claessen; Loes P Hoebers; Niels J Verouden; Jacques J Koolen; Maarten J Suttorp; Emanuele Barbato; Matthijs Bax; Bradley H Strauss; Göran K Olivecrona; Vegard Tuseth; Dietmar Glogar; Truls Råmunddal; Jan G Tijssen; Jan J Piek; José P S Henriques
Journal:  Trials       Date:  2010-09-21       Impact factor: 2.279

10.  Coronary Revascularization in Cardiogenic Shock.

Authors:  Nathan Spence; J Dawn Abbott
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.